Linköping University Post Print Effects of the oral, direct thrombin inhibitor
... draw backs is the need for monitoring by measuring prothrombin time to achieve appropriate degree of anticoagulation. The inter-individual variation in weekly dosage is ten-fold, depending on many causes, for example intake of vitamin K with the food, polymorphisms in the liver enzymes degrading the ...
... draw backs is the need for monitoring by measuring prothrombin time to achieve appropriate degree of anticoagulation. The inter-individual variation in weekly dosage is ten-fold, depending on many causes, for example intake of vitamin K with the food, polymorphisms in the liver enzymes degrading the ...
A Clinically Oriented Review of the Landmark Clinical Trials
... no difference in the rates of clinically relevant bleeding. However, using an intention-to-treat analysis, there were significantly fewer primary events (stroke or systemic embolism) in patients taking rivaroxaban compared to patients taking warfarin during the treatment period (1.7% versus 2.2%, P= ...
... no difference in the rates of clinically relevant bleeding. However, using an intention-to-treat analysis, there were significantly fewer primary events (stroke or systemic embolism) in patients taking rivaroxaban compared to patients taking warfarin during the treatment period (1.7% versus 2.2%, P= ...
alprolix - Biogen Canada
... Factor IX (FIX) is an approximately 55 kDa vitamin K-dependent serine protease, which is an essential clotting factor in the coagulation cascade critical to the hemostasis process. FIX is normally converted to activated FIX (FIXa) by the activated factor VII/Tissue Factor complex or by activated fac ...
... Factor IX (FIX) is an approximately 55 kDa vitamin K-dependent serine protease, which is an essential clotting factor in the coagulation cascade critical to the hemostasis process. FIX is normally converted to activated FIX (FIXa) by the activated factor VII/Tissue Factor complex or by activated fac ...
Histone Deacetylase Inhibitors: Updated Studies in Various
... The pharmacophore of HDACi possesses usually the following well-known components: a cap group (CAP) allowing to interact with the rim of the catalytic tunnel of the enzyme, a polar connection unit (CU, apparently dispensable for HDAC8 selective inhibitors) connecting to a hydrophobic spacer (HS) ena ...
... The pharmacophore of HDACi possesses usually the following well-known components: a cap group (CAP) allowing to interact with the rim of the catalytic tunnel of the enzyme, a polar connection unit (CU, apparently dispensable for HDAC8 selective inhibitors) connecting to a hydrophobic spacer (HS) ena ...
Grand Canonical Monte Carlo Simulation of Ligand−Protein Binding
... inhibitors17 and thrombin.18 However, these methods require calibration using a set of known ligand-protein binding energies, as well as prior knowledge of the binding site. In this report, we describe an alternative approach that computes binding free energies for a large number of poses over the p ...
... inhibitors17 and thrombin.18 However, these methods require calibration using a set of known ligand-protein binding energies, as well as prior knowledge of the binding site. In this report, we describe an alternative approach that computes binding free energies for a large number of poses over the p ...
A guide to drug discovery — opinion: Finding the sweet spot: the
... CYP2C19, CYP2D6 and CYP3A4. These rules, often referred to as the GlaxoSmithKline 4/400 rule, suggest that compounds with a cLogP >4 and molecular mass >400 Da have a less favourable ADMET profile12. Large-scale analysis13 of more than 200,000 compounds (available from the ChEMBL database) revealed ...
... CYP2C19, CYP2D6 and CYP3A4. These rules, often referred to as the GlaxoSmithKline 4/400 rule, suggest that compounds with a cLogP >4 and molecular mass >400 Da have a less favourable ADMET profile12. Large-scale analysis13 of more than 200,000 compounds (available from the ChEMBL database) revealed ...
Use of angiotensin receptor antagonists in patients with ACE
... Additional information on the safety aspects of ARAs was provided by the National Pharmacovigilance Center in our country (The Netherlands Pharmacovigilance Centre Lareb) and the Uppsala Monitoring Center (UMC) of the World Health Organization (WHO) in Sweden. In the period from 1 May 1996 to 1 Nove ...
... Additional information on the safety aspects of ARAs was provided by the National Pharmacovigilance Center in our country (The Netherlands Pharmacovigilance Centre Lareb) and the Uppsala Monitoring Center (UMC) of the World Health Organization (WHO) in Sweden. In the period from 1 May 1996 to 1 Nove ...
Studies of the Biogenic Amine Transporters. 12. Identification of
... Fig. 5. Effect of SoRI-20041 on the hDAT Bmax and Kd values. Two concentrations of [125I]RTI-55 (0.01 and 1.0 nM) were each displaced by 10 concentrations of RTI-55 (0.01–102 nM) in the absence and presence of the indicated concentrations of SoRI-20041. The data of three independent experiments were ...
... Fig. 5. Effect of SoRI-20041 on the hDAT Bmax and Kd values. Two concentrations of [125I]RTI-55 (0.01 and 1.0 nM) were each displaced by 10 concentrations of RTI-55 (0.01–102 nM) in the absence and presence of the indicated concentrations of SoRI-20041. The data of three independent experiments were ...
Enhanced water solubility for enhanced oral drug delivery via the
... Germany), a direct thrombin inhibitor for stroke prevention, which has been available in Europe and many other countries since 2008. However, it was not until the October 2010 when dabigatran etexilate became the first oral alternative to warfarin to be approved in the United States. The active drug ...
... Germany), a direct thrombin inhibitor for stroke prevention, which has been available in Europe and many other countries since 2008. However, it was not until the October 2010 when dabigatran etexilate became the first oral alternative to warfarin to be approved in the United States. The active drug ...
Clinical Strategies for Selecting Oral Anticoagulants in Patients
... renal insufficiency showed non-inferiority to warfarin for the primary safety endpoint, which mirrored the overall trial results. Moderate renal impairment patients had decreased fatal bleeding relative to warfarin, as seen in the cohort with normal to mild renal insufficiency, and similar levels of ...
... renal insufficiency showed non-inferiority to warfarin for the primary safety endpoint, which mirrored the overall trial results. Moderate renal impairment patients had decreased fatal bleeding relative to warfarin, as seen in the cohort with normal to mild renal insufficiency, and similar levels of ...
Pharmacokinetics Warfarin
... • The interaction of aspirin and warfarin is due to warfarin being displaced from protein binding sites causing an increased INR. False (It doesn’t displace binding sites) • Low Extraction Drug: Css,u= D/Clint • A chronic alcoholic can be expected to have consistently decreased INR. True • Patients ...
... • The interaction of aspirin and warfarin is due to warfarin being displaced from protein binding sites causing an increased INR. False (It doesn’t displace binding sites) • Low Extraction Drug: Css,u= D/Clint • A chronic alcoholic can be expected to have consistently decreased INR. True • Patients ...
Curr.Med. Chem._Martínez, A._2015 - digital
... neurodegenerative disorders, cancers and cardiovascular diseases. The rationale behind these bitopic inhibitors together with their development of multitarget drugs is described. The main goal of this review is to describe the evolution from the first dual binding site AChE inhibitors to molecules ...
... neurodegenerative disorders, cancers and cardiovascular diseases. The rationale behind these bitopic inhibitors together with their development of multitarget drugs is described. The main goal of this review is to describe the evolution from the first dual binding site AChE inhibitors to molecules ...
Sulodexide - Wiley Online Library
... Survivors of acute myocardial infarction are at high risk for the recurrence of thrombosis and sudden cardiac arrest is a major health problem, causing about 330,000 deaths each year among U.S. adults either before reaching a hospital or in an emergency room. Major research efforts in academic setti ...
... Survivors of acute myocardial infarction are at high risk for the recurrence of thrombosis and sudden cardiac arrest is a major health problem, causing about 330,000 deaths each year among U.S. adults either before reaching a hospital or in an emergency room. Major research efforts in academic setti ...
Asthma
... Physicians and patients view COPD differently. A 2002 study that showed that because combined therapy with inhaled corticosteroids and long-acting ßagonists produced a larger benefit than either therapy alone, it was easier to notice the difference in lung function and symptoms. • Each of these stud ...
... Physicians and patients view COPD differently. A 2002 study that showed that because combined therapy with inhaled corticosteroids and long-acting ßagonists produced a larger benefit than either therapy alone, it was easier to notice the difference in lung function and symptoms. • Each of these stud ...
Amber Initiation Guideline
... possible due to the patient’s medical condition, the decision will be made as considered in the best interests of the patient. This initiation may be undertaken by the secondary care stroke service rather than by the NOAC clinic, for secondary prevention of stroke or TIA to prevent delay in treatmen ...
... possible due to the patient’s medical condition, the decision will be made as considered in the best interests of the patient. This initiation may be undertaken by the secondary care stroke service rather than by the NOAC clinic, for secondary prevention of stroke or TIA to prevent delay in treatmen ...
Herb-drug interactions
... Foods: leafy greens (healthy diet) Multivitamins (low vitamin K dose) CoQ10: similar structure to vitamin K, but RCT found no effect on INR. Case reports suggest monitoring. ...
... Foods: leafy greens (healthy diet) Multivitamins (low vitamin K dose) CoQ10: similar structure to vitamin K, but RCT found no effect on INR. Case reports suggest monitoring. ...
Molecular Docking and ADMET Study of Emodin Derivatives as
... 1(a), Figure 1(b)), the bond formed involved Ser287---OH (3.28 Å), the hydroxyl group (OH) which formed the hydrogen bond with amino acid Ser287 was from the ring B (Figure 2(a)). The other four hydrogen bond were contributed from the rhamnoside moiety which includes; Ser287---OH (3.16 Å), Thr289--- ...
... 1(a), Figure 1(b)), the bond formed involved Ser287---OH (3.28 Å), the hydroxyl group (OH) which formed the hydrogen bond with amino acid Ser287 was from the ring B (Figure 2(a)). The other four hydrogen bond were contributed from the rhamnoside moiety which includes; Ser287---OH (3.16 Å), Thr289--- ...
Introduction to Inhibitors
... maximum after exposure to inhibitory molecule for a selected period of time. This term is used usually with ...
... maximum after exposure to inhibitory molecule for a selected period of time. This term is used usually with ...
Intro to Inhibitors-MM edition-final
... maximum after exposure to inhibitory molecule for a selected period of time. This term is used usually with ...
... maximum after exposure to inhibitory molecule for a selected period of time. This term is used usually with ...
Selective phosphodiesterase inhibitors for the treatment
... target for novel anti-inflammatory drugs, since this isoenzyme family is represented in all cells, with the exception of platelets, that are thought to be involved in inflammatory reactions [23]. PDE4, the low Km cAMP-specific isozyme, is the major cAMP-metabolizing enzyme in immune and inflammatory ...
... target for novel anti-inflammatory drugs, since this isoenzyme family is represented in all cells, with the exception of platelets, that are thought to be involved in inflammatory reactions [23]. PDE4, the low Km cAMP-specific isozyme, is the major cAMP-metabolizing enzyme in immune and inflammatory ...
Antiretroviral Agents presentation
... RDEA806 phase 2a data presented on this NNRTI with an in vitro high barrier to resistance and activity against isolates resistant to current NNRTIs. It may be important that its metabolic pathway does not appear to have any significant effect on other drugs. Previous work in healthy volunteers had s ...
... RDEA806 phase 2a data presented on this NNRTI with an in vitro high barrier to resistance and activity against isolates resistant to current NNRTIs. It may be important that its metabolic pathway does not appear to have any significant effect on other drugs. Previous work in healthy volunteers had s ...
Carbonic Anhydrase Inhibitors and Activators: Small
... the mere existence of such a class of CA activity modulators. This topic, then, received little attention from the scientific community for at least two reasons: (i) the statement by Clark and Perrin (1951) that activators of CA do not exist and (ii) the idea that the reported activation is not a ph ...
... the mere existence of such a class of CA activity modulators. This topic, then, received little attention from the scientific community for at least two reasons: (i) the statement by Clark and Perrin (1951) that activators of CA do not exist and (ii) the idea that the reported activation is not a ph ...